Financière de Tubize S.A.
TUB.BR
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.57B
Close$
$0.01
100% downside
Current Fair Value
100% downsideOvervalued by 100% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.57 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $1.12 (0.66%) |
| Earnings per Share | $2.09 |
| Beta | 0.4 |
| Outstanding Shares | 44,512,598 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 77.02 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Financière de Tubize S.A.
3 employees
CEO: Eric Nys Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.